This can stimulate angiogenesis at sites of tissue disruption in animal models ERK1/2 activation: Studies in preclinical settings have observed activation of extracellular signal-regulated kinases
Clinical evidence shows: Reduced caloric intake by 18% , comparable to the 24% reduction observed in the STEP 1 trial for Ozempic Increased endogenous GLP-1 and CCK secretion six-fold , roughly doubling normal post-meal hormone release Decreased hunger by 30% and food cravings by 40% in both men and women Improved post-prandial glucose control without raising insulin Effects observed within one hour of dosing , lasting 46 hours, in sync with natural gut hormone rhythms CaloCurb Clinical doubles the Amarasate concentration compared to retail formulas (250 mg vs 125 mg), enhancing GLP-1 and CCK output for stronger appetite control
I love the flavor and I will definitely be buying this product again, except I'll purchase in bulk
In preclinical studies, it has been used in doses that translate to about 150mcg/daily
Research published in Nature Metabolism in 2025 found that these SCFAs function as important metabolic regulators, linking dietary fiber intake to cellular and metabolic function
PMCID: PMC3296184